The tail end of a hormone
AOD-9604 corresponds to residues 176 to 191 of human growth hormone, the C-terminal section. The idea behind isolating it was that this region carried the fat-metabolism activity without the growth and glucose effects of the full hormone.
That is a clean hypothesis and a legitimate line of research. Separating a wanted activity from unwanted ones is how a great deal of useful pharmacology has been done.
The assumption underneath the design is that a hormone’s activities are modular, that a section of the chain can be lifted out with one job intact and the rest left behind. Sometimes that holds. Where it does not, the fragment simply fails to reproduce what the parent molecule does, and only testing settles which of the two cases you are in.
A trial that reported honestly
The compound went into human clinical testing for obesity. The published results did not show a significant weight difference against placebo, and the programme did not continue on that indication.
This is the part worth sitting with. AOD-9604 has something almost nothing else in this space has, a real human trial, and what that trial found was an absence of effect. Pages that promote it rarely mention this.
A null finding is not the same as no finding. It narrows the range of things a compound plausibly does at the exposures tested, against the endpoint chosen, more than can be said for most of the material sold under the research use only label. It simply narrows that range in an unhelpful direction.
| Corresponds to | hGH residues 176–191 |
| Design intent | Fat metabolism without growth effects |
| Human trials | Yes, conducted for obesity |
| Trial outcome | No significant difference vs placebo |
| Stocked here | No, reference page |
| Closest products | GH secretagogues, tesamorelin |
| Evidence quality | Better than most; result was negative |
| Category | Research use only |
Identity and handling, set out plainly. No outcome is asserted.
We do not supply AOD-9604
Not because it is dangerous, but because we would be selling a compound whose best available human evidence points the wrong way, and we would rather explain that than take the order.
If growth hormone research is what you are after, the secretagogues in the catalogue act on release rather than on a fragment, and tesamorelin has an approval behind it. Those pages are linked below.
People who search for what is AOD-9604 are generally looking for a metabolic shortcut, and the reply that follows from the record is that the compound was built for precisely that purpose and did not deliver it. Where metabolic research is the genuine interest, the weight and metabolism area collects the compounds whose evidence runs the other way.
Checking the record for yourself
None of this has to be taken on our word, and it should not be. Registered studies and indexed publications are both public, and two searches will settle in a couple of minutes what a product description spends several paragraphs avoiding. The registry entries on ClinicalTrials.gov show what was studied and how each study was framed.
The published side sits on PubMed, where the animal work and the human work can be told apart by reading abstracts rather than the marketing built on top of them. Every supplier listing this compound has access to exactly the same two searches.
That is why a page like this belongs on a supplier’s site and not only on a critic’s. Quoting selectively from a mixed record is one of the patterns set out on the supplier warning signs page, and it is easiest to catch when the primary sources are one click away from the claim.
AOD-9604 in the catalogue
Purity confirmed to a 99% minimum, with documentation for the lot you receive.
Where AOD-9604 fits in
The surrounding topics, if you want them.
About AOD-9604
The questions that arrive by email.